mesmulogene ancovacivec
AXP000181.1 · Cancer vaccine
- Platform
- MVA
- Targets
- MUC1
- Originator
- Transgene
- Sponsor
- Transgene
Names
Virus
- Role
- Vaccine vector
- Family
- Poxviridae
- Virus
- vaccinia virus (NCBI Taxonomy 10245)
- Strain
- MVA
- Replication
- non replicating
- Modifications
- MUC1 and IL-2 cassettes inserted into MVA
- Transgenes
- MUC1, IL2
- Route
- subcutaneous
- Source
- evidence
Cross-references
- NCI Thesaurus
- C2241
- FDA UNII
- WQQ9XZH2CC
Approvals
No regulatory approval recorded.
Clinical trials (5)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT03353675 | A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With the Therapeutic Vaccine Named TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC) | Completed | Phase 2 | 2018-01-05 | 2019-11-20 | 44 | Non Small Cell Lung Cancer Metastatic |
| NCT02823990 | TG4010 and Nivolumab in Patients With Lung Cancer | Completed | Phase 2 | 2016-12-14 | 2021-02-24 | 13 | Recurrent Non-Small Cell Lung Carcinoma; Stage I Non-Small Cell Lung Cancer; Stage II Non-Small Cell Lung Cancer; Stage IIIA Non-Small Cell Lung Cancer; Stage IIIB Non-Small Cell Lung Cancer; Stage IV Non-Small Cell Lung Cancer |
| NCT01383148 | Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer | Terminated | Phase 2/3 | 2012-04 | 2015-07 | 222 | Non-Small-Cell Lung Carcinoma |
| NCT00415818 | Immunotherapy With TG4010 in Patients With Advanced Non-Small Cell Lung Cancer | Completed | Phase 2/3 | 2005-12 | 2010-03 | 148 | Carcinoma, Non-Small-Cell Lung |
| NCT00040170 | Vaccine Study of MVA-MUC1-IL2 in Patients With Prostate Cancer | Terminated | Phase 2 | 2002-05 | 50 | Prostatic Neoplasms |
Unconfirmed matches (1)
Trials that mention one of the names in a weaker way (a code only in the title, a short or ambiguous name). Not counted above.
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions | Matched by |
|---|---|---|---|---|---|---|---|---|
| NCT00004881 | Vaccine Therapy in Treating Patients With Advanced Cancer | Completed | Phase 1 | 2000-04 | Unspecified Adult Solid Tumor, Protocol Specific | name in intervention: MVA-MUC1-IL2 |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 42684015 | A phase II multi-institutional single arm trial evaluating TG4010 vaccine plus nivolumab in non-small cell lung cancer. | Oncoimmunology | 2026 | name in title: TG4010 |
| PMID 28923084 | Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC. | Journal for immunotherapy of cancer | 2017 | cited by trial NCT01383148 |
| PMID 26727163 | TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial. | The Lancet. Oncology | 2016 | cited by trial NCT01383148 |
| PMID 26207902 | Impact of TG4010 Vaccine on Health-Related Quality of Life in Advanced Non-Small-Cell Lung Cancer: Results of a Phase IIB Clinical Trial. | PloS one | 2015 | name in title: TG4010 |
| PMID 21069322 | A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings. | Cancer immunology, immunotherapy : CII | 2011 | name in title: TG4010 |
| PMID 22019520 | Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial. | The Lancet. Oncology | 2011 | cited by trial NCT00415818 |
| PMID 18931824 | MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure. | Investigational new drugs | 2009 | name in title: MVA-MUC1-IL2 |
| PMID 18594319 | A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2008 | name in title: MVA-MUC1-IL2 |
| PMID 17935281 | Cancer immunotherapy: phase II clinical studies with TG4010 (MVA-MUC1-IL2). | Journal of B.U.ON. : official journal of the Balkan Union of Oncology | 2007 | name in title: MVA-MUC1-IL2 |
| PMID 12898638 | Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer. | The journal of gene medicine | 2003 | name in abstract: TG4010 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41002418 | Advances in Non-Small Cell Lung Cancer Cellular Immunotherapy: A Progress in Dendritic Cell, T-Cell, and NK Cell Vaccines. | Cells | 2025 | name in abstract: TG4010 |
| PMID 38470132 | Therapeutic vaccines for advanced non-small cell lung cancer. | The Cochrane database of systematic reviews | 2024 | name in abstract: TG4010 |
| PMID 29714142 | Efficacy and Safety of Antigen-specific Immunotherapy in the Treatment of Patients with Non-small-cell Lung Cancer: A Systematic Review and Meta-analysis. | Current cancer drug targets | 2019 | name in abstract: TG4010 |
| PMID 30626434 | Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics. | Journal for immunotherapy of cancer | 2019 | name in abstract: MVA-MUC1-IL2 |
| PMID 28925793 | Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model. | Human vaccines & immunotherapeutics | 2018 | name in title: TG4010 |
| PMID 28012777 | Sequential administration of a MVA-based MUC1 cancer vaccine and the TLR9 ligand Litenimod (Li28) improves local immune defense against tumors. | Vaccine | 2017 | name in abstract: TG4010 |
| PMID 28116088 | Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen. | Journal for immunotherapy of cancer | 2017 | name in title: MVA-MUC1-IL2 |
| PMID 27140406 | TG4010: a vaccine with a therapeutic role in cancer. | Immunotherapy | 2016 | name in title: TG4010 |
| PMID 27275498 | TG4010 immunotherapy: a novel weapon against advanced non-small cell lung cancer? | Annals of translational medicine | 2016 | name in title: TG4010 |
| PMID 27563655 | Immunotherapy in non-small cell lung cancer: the clinical impact of immune response and targeting. | Annals of translational medicine | 2016 | name in abstract: TG4010 |
| PMID 24143916 | Immunotherapy for lung cancer: ongoing clinical trials. | Future oncology (London, England) | 2014 | name in abstract: TG4010 |
| PMID 24196313 | Recent advances in immunotherapy for non-small-cell lung cancer. | Human vaccines & immunotherapeutics | 2014 | name in abstract: TG4010 |
| PMID 25030654 | Immunotherapeutic agents in non-small-cell lung cancer finally coming to the front lines. | Current oncology reports | 2014 | name in abstract: TG4010 |
| PMID 25496336 | Immunotherapy and lung cancer: current developments and novel targeted therapies. | Immunotherapy | 2014 | name in abstract: TG4010 |
| PMID 23401435 | Harnessing the immune system for the treatment of non-small-cell lung cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2013 | name in abstract: TG4010 |
| PMID 23867519 | A new age for vaccine therapy in renal cell carcinoma. | Cancer journal (Sudbury, Mass.) | 2013 | name in abstract: TG4010 |
| PMID 27471692 | Therapeutic vaccines in non-small cell lung cancer. | ImmunoTargets and therapy | 2013 | name in abstract: TG4010 |
| PMID 22156658 | Vaccination therapy for non-small-cell lung cancer: review of agents in phase III development. | Annals of oncology : official journal of the European Society for Medical Oncology | 2012 | name in abstract: TG4010 |
| PMID 22934285 | TG4010: A therapeutic vaccine against MUC1 expressing tumors. | Oncoimmunology | 2012 | name in title: TG4010 |
| PMID 21154139 | Biological Therapeutics Research and Development--GTCbio's Fifth Annual Conference. October 20-22, 2010, San Francisco, CA, USA. | IDrugs : the investigational drugs journal | 2010 | name in abstract: TG4010 |
| PMID 19649342 | Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology | 2009 | name in abstract: TG4010 |
| PMID 14988742 | Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology | 2004 | name in abstract: MVA-MUC1-IL2 |
| PMID 15648954 | TG-4010 Transgene. | Current opinion in investigational drugs (London, England : 2000) | 2004 | name in title: TG4010 |
Notes
TG4010: MVA encoding MUC1 and human IL-2, subcutaneous, in first-line advanced NSCLC with chemotherapy; randomised phase 2b (TIME) reported 2016. MVA strain lineage recorded as MVA; specific MVA stock not verified here.
How to cite
mesmulogene ancovacivec (AXP000181.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000181.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.